Destiny Pharma PLC is a UK-based clinical stage biotechnology company which focuses on developing novel anti-infectives mainly for infection prevention. It was founded in the year 1997 and its headquarters are situated at The University of Sussex in Brighton, United Kingdom. The company is listed on the alternative investment market of the London Stock Exchange since 2017 raising over £15 million along with an additional £3 million by collaborating with China Medical Systems. The company is a constituent of the FTSE AIM All-Share index. It complies with the UK City Code on Takeovers.
The aim of the company is to discover, develop, and commercialise new antimicrobials with distinctive properties for the improvement of results for patients. The unique features of its wide range of anti-microbial drug products helps the company in expanding into new markets that have closed their doors for traditional antibiotics because of the existing threats related to antibiotic resistance. The XF Drugs Series, which is Destiny Pharma’s proprietary, anti-microbial drug platform, functions through an ultra-rapid action which destroys the bacteria, including the antibiotic resistant strains, which in turn leaves the bacteria powerless to launch a resistance response. Apart from XF platform, its technologies also include biotherapeutics. Two new medicine product programs have been recently established in 2020 by the company to prevent infections using biotherapeutic products. These include NTCD-M3 and SPOR-COV. In addition to antimicrobial resistance, its target markets include Clostridioides difficile Infections (CDI), Post-Surgical Infections, Dermal Infections, and Covid-19.
Destiny Pharma PLC follows a well-defined framework of corporate governance and aligns itself with the Quoted Companies Alliance (QCA) Corporate Governance Code. Its board has set up separate committees for audit, remuneration, and nomination. It has an ethical code of conduct for running its business operations and promotes a culture of trust, transparency, accountability. It actively works with customers, suppliers, employees and partners under a responsible business framework. In addition to corporate responsibilities, the company also fulfils its environmental and social responsibilities and complies with international best practices and guidelines to create a sustainable business. It aims to minimize the impact of its business activities on the environment and create long-term value for the business as well as the wider community.
Destiny Pharma PLC Sussex Innovation Centre Science Park Square, Falmer BRIGHTON BN1 9SB United Kingdom GBR
+44 127 370 4440